bluuebunny/crossref_metadata_2025_split huggingface dataset:
DENTIFIKASI JENIS BAMBU DI BLOK GUNUNG PUTRI SPTN WILAYAH I TAMAN NASIONAL GUNUNG CIREMAI
Authors: Purnama Asep Iman , Herlina Nina , Hendrayana Yayan 
Published: March 2024

Bamboo in Indonesia natural habitats grows in groups because of its reproduction through shoots. Ecologically, according to Widnyana (2011) the roots of bamboo rhizomes will be able to maintain the hydrological system as a binder of soil and water, so that it can be used as a conservation plant. There is information based on residents around the Gunung Putri TNGC block that there is no known type of bamboo in the Gunung Putri TNGC block whose growth is spreading. This study aims to determine and identify the morphological characters of each type of bamboo in the Gunung Putri Block SPTN Region I TNGC covering an area of 163.16 hectares at an altitude of 1000-1800m above sea level. The method used is the method of observation, exploration and data analysis. In Block Gunung Putri SPTN Region I Gunung Ciremai National Park, 3 types of bamboo were found, including G.apus (Bamboo Tali), G.atter (Bamboo Temen), and D.scandens (Bamboo Cangkoreh). In the Gigantochloa clan, the key character is with one main branch being larger than the branch, whereas in the Dinocloa clan the key character is the monopodial rhizome root, the branches only grow far from the ground, the trunk is small spreading among other trees, not clumping.Bambu di habitat alami Indonesia tumbuh berkelompok karena perkembangbiakannya melalui pucuk. Secara ekologis menurut Widnyana (2011) akar rimpang bambu akan mampu menjaga sistem hidrologi sebagai pengikat tanah dan air, sehingga dapat dimanfaatkan sebagai tanaman konservasi. Berdasarkan informasi warga di sekitar blok Gunung Putri TNGC, tidak diketahui jenis bambu di blok Gunung Putri TNGC yang pertumbuhannya menyebar. Penelitian ini bertujuan untuk mengetahui dan mengidentifikasi karakter morfologi tiap jenis bambu di SPTN Blok Gunung Putri Wilayah I TNGC seluas 163,16 Ha pada ketinggian 1000-1800m dpl. Metode yang digunakan adalah metode observasi, eksplorasi dan analisis data. Di Blok Gunung Putri SPTN Wilayah I Taman Nasional Gunung Ciremai ditemukan 3 jenis bambu, antara lain G.apus (Bambu Tali), G.atter (Bambu Temen), dan D.scandens (Bambu Cangkoreh). Pada marga Gigantochloa karakter kuncinya adalah dengan salah satu cabang utama lebih besar dari cabangnya, sedangkan pada marga Dinocloa karakter kuncinya adalah akar rimpang yang monopodial, cabangnya hanya tumbuh jauh dari permukaan tanah, batangnya kecil-kecil menyebar di antara pohon-pohon lain. , tidak menggumpal.
STRUKTUR POPULASI DAN SEBARAN SERTA KARAKTERISTIK HABITAT HURU SINTOK (Cinnamomum sintocBl) DI RESORT CILIMUS TAMAN NASIONAL GUNUNG CIREMAI
Authors: Ismail Agus Yadi , Nasihin Iing , Juhendar Didin 
Published: March 2024

Taman Nasional Gunung Ciremai merupakan salah satu kawasan konservasi yang berada di Propinsi Jawa Barat.Kawasan konservasi memiliki fungsi utama sebagai perlindungan keanekaragaman hayati. Penelitian ini bertujuan untuk mengetahui struktut populasi, sebaran spasial dan karakteristik habitat Huru Sintok di kawasan Resort Cilimus, Taman Nasional Gunung Ciremai. Penelitian ini dilakukan pada bulan Maret sampai April 2015. Data yang digunakan berupa sekunder meliputi kondisi umum lokasi dan data primer meliputi data titik koordinat, analisis vegetasi, nama spesies, jumlah individu setiap spesies, diameter batang, tinggi pohon, kelerengan, ketinggian tempat, dan suhu lokasi pengamatan. Pengolahan data dilakukan dengan menggunakan Indeks Nilai Penting (INP), Indeks Dominansi (C), Indeks Keanekaragaman Shannon-Wiener (H’), Indeks Kemerataan (E) dan Indeks Kekayaan Jenis (R).Hasil penelitian menunjukkan bahwa struktur populasi Huru Sintok berbentuk piramida dengan dasar yang luas artinya banyaknya pohon paling banyak dijumpai pada kelas umur rendah dan semakin menurun dengan bertambahnya kelas diameter, hasil ini menunjukkan bahwa Huru Sintok dapat beregenerasi dengan baik yang terlihat dengan jumlah semai yang melimpah. Sebaran Huru Sintok cenderung individual dan jarang ditemukan mengelompok. Adanya pohon Huru Sintok yang ditemukan di kawasan penelitian diduga karena Huru Sintok dapat beradaptasi dengan baik di habitat pada kawasan hutan Resort Cilimus yang masih kaya akan unsur organik karena hutan tersebut merupakan kawasan konservasi. Karakteristik habitat Huru Sintok dijumpai dengan ketinggian 500-1100 m dpl, dengan kelerengan mulai dari 10-45 %, suhu mulai dari 19-26°C dan vegetasi penyusun Huru Sintok didominasi oleh famili Lauraceae dan Euphorbiaceae.Kata Kunci : Huru Sintok, Struktur Populasi, Sebaran Spasial, Karakteristik Habitat.
Verrucous Cyst in a 7-year-old Girl
Authors: Anaba Ehiaghe , Rasheed Mumini Wemimo 
Published: March 2024

Background: Verrucous cyst is an uncommon manifestation of human papilloma virus infection. Diagnosis is histopathological and characterized by verrucous changes in an epidermal cyst. This is a report of verrucous cyst in a seven (7) year old girl who had an asymptomatic nodule on her hand.
Case Report: 7-year old girl who had a nodule on the palmar surface of her left hand. A clinical diagnosis of foreign body granuloma was made. Biopsy and histopathology was consistent with a verrucous cyst
Conclusion: The need for histopathological evaluation of skin growths is highlighted by this case report.
The Association Between Internet Search Patterns and Scabies Incidence Across the United States
Authors: Sparling Kennedy , Dhupati Pooja 
Published: March 2024

Background
Scabies, a contagious skin infestation caused by Sarcoptes scabiei, is a significant public health concern [1]. Traditional surveillance methods for scabies suffer from time lag and incomplete data, hindering early detection and response [5]. The widespread use of the internet and search engines, such as GoogleTM, offer new opportunities for alternative surveillance approaches.
Objective
This study aimed to explore the association between scabies search volumes on Google TrendsTM (GTs) and scabies incidence at the state level across the United States.
Methods
GTs data for each U.S. state and scabies incidence from 2011 to 2019 were analyzed for summary statistics and association.
Results
The mean Spearman correlation coefficient for the period of 2011-2019 indicated a strong positive correlation between GTs RSVs for “scabies” and the incidence of scabies in the United States. Using an unpaired t-test, this correlation was found to be statistically significant.
Conclusions
In resource-scarce environments where access to care is a common barrier, healthcare providers and departments can leverage this information to effectively target populations and employ resources for scabies prevention and treatment. Analyzing search engine term patterns can enhance our understanding of people's behavior when they suspect a scabies infestation.
Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial
Authors: Strober Bruce , Mostaghimi Arash , Anadkat Milan , Thoma Christian , Tang Ming , Guercio Jason , Lebwohl Mark 
Published: March 2024

Introduction & Objectives: Generalized pustular psoriasis (GPP) is a chronic inflammatory, and potentially life-threatening skin disease, characterized by flares of sterile pustules. Spesolimab is approved to treat GPP flares in adults. Effisayil 2 (NCT04399837) evaluated the efficacy and safety of subcutaneous spesolimab in preventing GPP flares. Here, we report on the underlying disease burden of untreated GPP by longitudinally analyzing patients in the placebo group who did not experience a GPP flare.
Materials & Methods: Eligible patients with a history of GPP were randomized (1:1:1:1) to receive one of three subcutaneous spesolimab regimens or placebo for 48 weeks. Patients were assessed for measures of chronic disease burden through the use of Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) Total Score, Pain Visual Analog Scale (VAS), and Psoriasis Symptom Scale (PSS) at baseline and at 4-week intervals during the trial, and Dermatology Quality of Life Index (DLQI) at baseline and weeks 4, 8, 12, 24, 36, and 48.
Results: 16/31 placebo-treated patients experienced a GPP flare over the 48-week observational period of the trial, defined as an increase in GPPPGA score by ≥2 from baseline and the pustular component of GPPPGA ≥2. Of the remaining (“non-flaring”) 15 patients, 40% (6/15) had at least one GPPPGA Total Score value of 2 (skin not clear or almost clear); 4/6 reported such score at ≥4 visits. Pain scores ranged from 0 to 92.47, with 47% (7/15) and 20% (3/15) of patients having at least one “moderate” and “severe” VAS score over 48 weeks, respectively. Most of the 7 patients’ pain scores fluctuated with episodic peaks and valleys. 47% (7/15) and 13% (2/15) of patients had at least one “moderate” and “severe” PSS score, respectively. “Moderate” and “very large” effect on quality of life was reported, at least once, in 67% (10/15) and 40% (6/15) of patients, respectively.
Conclusion: Acute flare was reported in more than 50% (16/31) of patients in the placebo group over 48 weeks. Despite not meeting the trial’s definition of GPP flare, most of the 15 “non-flaring” placebo-treated patients showed clear evidence of underlying GPP disease activity – nearly half did not have “clear” or “almost clear” skin and had moderate pain and symptoms; a small subset reported severe pain and symptoms. Majority of patients experienced a moderate to very large impact on quality of life over the 48 weeks. These findings suggest that untreated GPP negatively affects patients even in the absence of acute flare events.
Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials
Authors: Reich Kristian , Langley Richard G. , Silvestre Juan Francisco , Staumont-Salle Delphine , Costanzo Antonio , Pink Andrew , Paller Amy , Katoh Norito , Wollenberg Andreas , Warren Richard B. , Øland Christian Bjerregård , Tindberg Ann-Marie , Gjerum Le , Simpson Eric 
Published: March 2024

Introduction: Clinical trials of up to 52 weeks showed that tralokinumab, a monoclonal antibody that specifically neutralizes interleukin-13, was efficacious and well-tolerated as monotherapy and combination with TCS. Here, we evaluate the long-term safety of tralokinumab in an integrated analysis of seven phase 3 parent trials (PTs) (NCT03131648, NCT03160885, NCT03363854, NCT03562377, NCT03526861, NCT03761537, NCT04587453), and the ongoing, up to 5-year extension study (ECZTEND; NCT03587805).
Methods: Two datasets were analyzed: placebo-controlled (initial 16-week period of the PTs), and all-tralokinumab combining PTs with ECZTEND including patients from first dose until end of tralokinumab exposure or data cut-off (April 30th, 2022). In the all-tralokinumab dataset, periods on placebo were disregarded. Treatment-emergent adverse events (AEs) were recorded. AEs of special interest (AESIs) were predefined. Proportions of patients with events and incidence rates (IR) per 100 patient-years of exposure (PYE) were calculated. PYE was defined as time until first event or exposure end, whichever came first, and incidence was defined as first event.
Results: 2693 patients (≥12 years) received tralokinumab for up to 238.5 weeks (≈4.5 years) with a median exposure time of 76.5 weeks in the all-tralokinumab dataset. Median age at baseline was 33.0 years (min-max; 12-92). 10.4% of patients were 12-17 years. 2307 patients experienced an AE (IR=202.0), most (97.3%) of which were mild-to-moderate. Serious AEs (SAEs) were reported in 226 patients (IR=4.5); SAEs were considered possibly or probably related by the investigator in 50 patients (IR=0.9). No preferred term level SAEs were reported with an IR≥0.1. Discontinuation of treatment due to AEs was low (IR=2.8). AEs leading to drug withdrawal with an IR>0.1 were dermatitis atopic (IR=0.5) and injection site reaction (ISR) (IR=0.2). Frequently reported AEs in the all-tralokinumab dataset were consistent with the placebo-controlled dataset, including nasopharyngitis (IR=18.4), upper respiratory tract infection (IR=6.9), conjunctivitis (IR=5.0), ISR (IR=3.6), conjunctivitis allergic (IR=2.7), and injection site pain (IR=1.5). AESIs, including eye disorders, skin infections requiring systemic treatment, eczema herpeticum, and malignancies, were observed in the all-tralokinumab dataset at rates similar to or lower than the placebo-controlled dataset.
Conclusion: Long-term use of tralokinumab, for up to 4.5 years, was well-tolerated, and the pattern of AEs was consistent with the initial placebo-controlled treatment period with no new safety signals identified.
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Clinical Efficacy and Application Characteristics
Authors: Draelos Zoe , Stein Gold Linda , Kircik Leon , Tanghetti Emil 
Published: March 2024

Background: Triple-combination therapies for acne including an antibiotic, topical retinoid, and benzoyl peroxide (BPO) are among the most effective, with meta-analyses demonstrating greater efficacy with triple-combinations than dual-combinations or topical monotherapy. However, this benefit may be offset by reduced adherence to a complicated treatment regimen. Here, the clinical efficacy of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% (CAB) gel is reviewed, and the ease of CAB application is compared with the layered application of its individual active ingredients.
Methods: In a phase 2 (N=741) and two phase 3 (N=183; N=180), double-blind, randomized, 12-week studies, participants aged ≥9 years with moderate-to-severe acne were randomized to receive once-daily CAB or vehicle; the phase 2 study also included treatment arms containing dyad gels (BPO/adapalene; clindamycin phosphate/BPO; clindamycin phosphate/adapalene). Efficacy endpoints included treatment success (percentage of participants achieving ≥2-grade reduction from baseline in Evaluator’s Global Severity Score and clear/almost clear skin) and reductions from baseline in inflammatory (IL) and noninflammatory lesions (NIL). In a split-face study of adults with acne-prone skin (N=25), participant-application of CAB (0.3 cc) was compared to sequential, layered application of benzoyl peroxide cream, adapalene gel, and clindamycin gel (0.1 cc each). IDP-126 and clindamycin gels were compounded with pyranine, which fluoresces under blue light; photos were taken under blue light to assess evenness of product application.
Results: In all three clinical studies at week 12, half of CAB-treated participants achieved treatment success (range: 49.6%-52.5%), significantly greater than with vehicle (8.1%-24.9%; P<0.01, all) or dyads (phase 2 study only; 27.8%-30.5%; P≤0.001, all). Reductions from baseline in both IL and NIL were also significantly greater for CAB vs vehicle (range, IL: 75.7%-80.1% vs 50.4%-59.6%; NIL: 71.0%-73.3% vs 45.8%-49.0%; P<0.001, all) and dyads (IL: 64.0%-69.2%; NIL: 58.7%-61.1%; P<0.01, all vs IDP-126). In the split-face study, 100% of Investigator and participant assessments of evenness of application favored CAB over the three layered products. In addition, all participants rated CAB as both easier and faster to apply, and most (96%) preferred CAB for use at home.
Conclusions: Fixed-dose CAB gel applied more evenly than separate application of its three active ingredients, and demonstrated significantly greater efficacy in the treatment of moderate-to-severe acne than dyad gels or vehicle. By addressing three of the main acne pathogenic pathways in a single, easy-to-apply formulation, CAB may improve efficacy of and adherence to acne treatment.
Funding: Ortho Dermatologics
Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Females with Moderate to Severe Acne: Post Hoc Analysis by Age
Authors: Harper Julie , Stein Gold Linda , Baldwin Hilary , Callender Valerie , Gold Michael , Woolery-Lloyd Heather , Kircik Leon 
Published: March 2024

Introduction: While acne is common in adolescents, the overall prevalence in adults is increasing, especially among females. In addition, acne in older females is associated with greater negative impacts on quality of life. Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% (CAB) gel—the first fixed-dose, triple-combination topical product approved for acne—has demonstrated good efficacy, safety, and tolerability in participants with moderate-to-severe acne. The objective of this analysis is to assess the impact of age on efficacy, safety, and tolerability in females with moderate-to-severe acne.
Methods: In one phase 2 (N=741; NCT03170388) and two identically designed phase 3 (N=183; N=180; NCT04214639; NCT04214652), double-blind, randomized, 12-week studies, participants aged ≥9 years with moderate-to-severe acne were randomized to receive once-daily CAB or vehicle gel; the phase 2 study included three additional dyad randomization arms (data not shown). Coprimary endpoints comprised inflammatory and noninflammatory lesion counts and treatment success (≥2-grade reduction from baseline in Evaluator’s Global Severity Score and score of ‘clear’ or ‘almost clear’). Treatment-emergent adverse events (TEAEs) and cutaneous safety and tolerability were also assessed. Pooled data from these studies were analyzed post hoc from female participants categorized by age: 9-24 years (n=274) and ≥25 years (n=121).
Results: At week 12 in both age groups, least-squares mean percent reductions from baseline were >70% in CAB-treated females versus vehicle gel for inflammatory (9-24 y: 77.8% vs 53.8%; ≥25 y: 77.8% vs 60.5%; P<0.01, both) and noninflammatory lesions (9-24 y: 72.8% vs 44.5%; ≥25 y: 73.7% vs 55.2%; P<0.001, both). Half of CAB-treated females in both age groups achieved treatment success at week 12 versus less than one-quarter with vehicle (9-24 y: 54.1% vs 15.6%; ≥25 y: 50.1% vs 22.5%; P<0.01, both). Most TEAEs were mild-to-moderate in severity, with rates similar to the overall pooled phase 2 and 3 populations. Although there were transient increases in the severity of cutaneous safety/tolerability assessments with CAB, scores generally returned to or near baseline levels for most assessments by week 12 in younger and older females. No notable age-related trends in safety were observed.
Conclusions: With greater than 70% lesion reductions and half of participants achieving treatment success by week 12, the innovative, fixed-dose triple combination clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel demonstrated good efficacy, safety, and tolerability in both younger and older females with moderate-to-severe acne.
Funding: Ortho Dermatologics
Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)
Authors: Davis Keith , Messenger Andrew , Vañó Galván Sergio , Tran Helen , Napatalung Lynne , Hanson Kent , Law Ernest 
Published: March 2024

Background: A range of medications with varying efficacy are used to treat alopecia areata (AA). There remains limited evidence on prevailing treatments, disease characteristics, and clinical outcomes of patients with AA in routine practice, particularly for those with extensive hair loss. This study sought to address this evidence gap.
Methods: This was a retrospective chart review study spanning the United Kingdom, France, Spain, and Germany. Adult and adolescent patients with ≥50% scalp hair loss were included. The study index date was defined as date of de novo or progression to ≥50% scalp hair loss and patients were required to have ≥6 months of postindex follow-up (i.e., index date to last clinic visit); index dates ranged 2015-2019. Analyses were descriptive and reported patient demographics, baseline clinical characteristics, and Dermatologic Life Quality Index (DLQI) score. The primary clinical endpoint was absolute Severity of Alopecia Tool (SALT) score and was assessed longitudinally based on post-index visits in which SALT was recorded. Sustained SALT ≤20 was also assessed via Kaplan-Meier methods to evaluate time to achieving SALT ≤20 without subsequent regression within 6 months to SALT >30.
Results: A total of 741 patients were included. Median age at AA diagnosis was 27 years and 52.6% were female. Mean (SD) baseline SALT score at index was 63.5 (15.6), with 80.2% having patchy AA and 19.8% having alopecia totalis or universalis. Among patients with DLQI measured at index, mean (SD) DLQI score was 19.2 (7.2) with 84.5% reporting either a large (DLQI 11-20) or extremely large (DLQI 21-30) impact of AA. Topical corticosteroids were the most common treatment observed post-index, with 55.6% receiving ≥1 course with a median cumulative exposure of 4 months. Intralesional corticosteroids (22.5%), systemic immunosuppressants (22.0%), and oral (17.3%) or topical (19.4%) minoxidil were also common. Among patients with SALT measured at 12 months post-index, there was a mean (SD) absolute SALT reduction of -44.6% (37.3%) from baseline. However, at 12 months post-index, most patients (90.1%) failed to achieve SALT ≤20 that was sustained for ≥6 months.
Conclusions: Although patients in this study experienced a substantial absolute SALT score reduction, few patients achieved and subsequentially sustained the more clinically meaningful SALT threshold of ≤20. These findings highlight the potential suboptimal effectiveness of the varied treatments applied in this population.